| ATM–Chk2–p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency L Cao, S Kim, C Xiao, RH Wang, X Coumoul, X Wang, WM Li, XL Xu, ... The EMBO Journal 25 (10), 2167-2177, 2006 | 143 | 2006 |
| PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? JA De Soto, CX Deng International Journal of Medical Sciences 3 (4), 117, 2006 | 93 | 2006 |
| The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors JA De Soto, X Wang, Y Tominaga, RH Wang, L Cao, W Qiao, C Li, X Xu, ... International journal of biological sciences 2 (4), 179, 2006 | 91 | 2006 |
| Using theoretical descriptors in quantitative structure–property relationships: some distribution equilibria DT Cronce, GR Famini, JA De Soto, LY Wilson Journal of the Chemical Society, Perkin Transactions 2, 1293-1302, 1998 | 54 | 1998 |
| The Pathophysiology of COVID-19 ST Hakim, FT Boyd, JA de Soto Journal of Virology Research & Reports 1 (2), 1-7, 2020 | 22 | 2020 |
| The use of PARP inhibitors as single agents and as chemosensitizers in sporadic pancreatic cancer. JA De Soto, R Mullins Journal of Clinical Oncology 29 (15_suppl), e13542-e13542, 2011 | 10 | 2011 |
| Sequence-and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells. JA De Soto, D Bowen, JH Davis, WM Southerland, M Hawkins Jr Anticancer research 22 (2A), 1007-1009, 2002 | 10 | 2002 |
| The Pathophysiology of Virulence of the COVID-19 J De Soto, S Hakim, F Boyd Preprints, 2020 | 9 | 2020 |
| Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy EB Fryar, JR Das, JH Davis, JA Desoto, I Laniyan, WM Southerland, ... Anticancer research 26 (3A), 1861-1867, 2006 | 9 | 2006 |
| Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies EB Fryar-Tita, JR Das, JH Davis, JA Desoto, S Green, WM Southerland, ... Anticancer research 27 (3B), 1393-1399, 2007 | 5 | 2007 |
| Medical Basis for Increased Susceptibility of COVID-19 among the Navajo and other Indigenous Tribes J De Soto, S Hakim Preprints, 2020 | 4 | 2020 |
| Medical Basis for Increased Susceptibility of COVID-19 among the Navajo and other Indigenous Tribes: A Survey J Angel de Soto J Biomed Res Rev 3, 37-41, 2020 | 3 | 2020 |
| The comparative efficacy of the PARP inhibitors AG14361, ABT888 and AZD2281 in the treatment of triple negative and BRCA1 breast cancer T Velikodvorskaya, N Fatima, RQ Fountain, JA De Soto Cancer Research 70 (8_Supplement), 663-663, 2010 | 3 | 2010 |
| Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection JH Davis, JA Desoto, EB Fryar, WM Southerland, D Bowen Cellular and Molecular Biology 53 (3), 18-26, 2007 | 3 | 2007 |
| Fighting the Monster: How Diné College Led the Navajo Nation's Response to COVID-19. ST Hakim, JA de Soto, G Joe, B Dotson Tribal College Journal of American Indian Higher Education 32 (4), n4, 2021 | 2 | 2021 |
| The treatment of clear cell ovarian cancer with the poly (ADP-ribose) polymerase (PARP1) inhibitors (AG14361, veliparib, olaparib) as chemosensitizers JA de Soto bioRxiv, 2020.11. 10.377424, 2020 | 2 | 2020 |
| The use of poly (ADP-ribose) polymerase (PARP1) inhibitors (AG14361, AZD2281, ABT888) in combination with capecitabine, 5-fluorouracil, or paclitaxel in the treatment of … JA De Soto, R Quick-Fountain, T Velikodvorskaya, N Fatima Journal of Clinical Oncology 28 (15_suppl), e13120-e13120, 2010 | 2 | 2010 |
| The systemic exclusion of Native Americans from cancer clinical trials HW Cayatineto, CS Clyde, GA Yazzie, G Selassie, JA de Soto Jour Med Resh and Health Sci 4 (8), 1396-1404, 2021 | 1 | 2021 |
| Evaluating the Sensitivity of Sporadic Pancreatic Cancer to poly (ADP-ribose) polymerase (PARP) Inhibition (Velaparib, Olaparib, AG14361) as Single Agents and as Chemo-sensitizers JA de Soto bioRxiv, 2020.03. 28.013763, 2020 | 1 | 2020 |
| Complementary Pharmacological Treatment and Therapeutic Prospects for COVID-19 JA De Soto, F DSSc, ST Hakim, D Fouast OSF, 2020 | 1 | 2020 |
Chuxia DengUniversity of MacauVerified email at umac.mo
